CIPLA · Cipla Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
11.9% below 52-week high
52-week range: as of 05 Nov 2026 close.
Slowest input: promoter pledge (disclosed quarterly), as of 18 Jul 2026
Stock Condition
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Stock Condition as of 05 Nov 2026 close
What the data shows
- Trend (10d)
- Sector standing
- Delivery (previous session)
- FII flow (5d)
- PCR
- RSI (14)
- Promoter pledge
- Insider activity (30d)
- Volume vs usual (5-day vs 20-day)
- 1.25x its usual level
- Growth trend
- Revenue grew 2.33% YoY last quarter (no multi-quarter acceleration streak on file).
- Valuation vs peers
- Trailing P/E of 35.11 sits inline the sector average of 36.32.
- Event risk (5d)
Data as of 05 Nov 2026
Data as of 05 Nov 2026
Data as of 04 Nov 2026
Data timestamp unavailable
Data as of 05 Nov 2026
Data as of 05 Nov 2026
Data as of 18 Jul 2026
Data timestamp unavailable
Data as of 05 Nov 2026
Data timestamp unavailable
Data timestamp unavailable
Data as of 02 Nov 2026 · 08:52 pm IST
Signal changes and why the Stock Condition changed
Why did this change?
CIPLA's Stock Condition eased from 55 to 53 on 5 Nov (-2).
- ▼Price trend: Trend reading weakened vs yesterday
- –Volume participation: volume held near its recent norm
- –Delivery participation: delivery held steady
- –Momentum (RSI): RSI held steady
- ▼Sector standing: industry standing weakened
- ▼Options positioning (PCR): options positioning shifted more call-heavy
- –Promoter pledge: promoter pledge unchanged
- –Insider activity: insider filings unchanged
- –FII flow context: FII flow backdrop unchanged
▲ improved · ▼ weakened · – unchanged
The data shows the change but not its cause — several explanations are usually possible.
Signal Change Log
- 05 Nov-2CIPLA's Stock Condition eased from 55 to 53 on 5 Nov (-2).
- 04 Nov-4Stock Condition eased 4 points on shifts across underlying measured values
- 03 Nov-11FII flows ran net-positive
- 03 Nov-11classified news events were recorded
- 03 Nov-11volume state cleared (volume elevated no longer applied)
- 02 Nov+11event state cleared (event risk no longer applied)
- 30 Oct+2price held above its 20-day average
- 29 Oct+1110-day trend turned positive
- 29 Oct+11delivery state cleared (delivery down no longer applied)
- 28 Oct-6delivery signal weakened
- 27 Oct-9volume ran above its recent norm
- 27 Oct-9classified news events were recorded
- 27 Oct-9trend state cleared (trend up 10d no longer applied)
- 27 Oct-9options state cleared (pcr call heavy no longer applied)
- 26 Oct+1110-day trend turned positive
- 26 Oct+11trend state cleared (below 20dma no longer applied)
- 23 Oct-6Stock Condition eased 6 points on shifts across underlying measured values
- 22 Oct+3delivery state cleared (delivery up no longer applied)
- 22 Oct+3fii state cleared (fii sell streak no longer applied)
- 21 Oct+5delivery signal strengthened
- 19 Oct+3Stock Condition rose 3 points on shifts across underlying measured values
- 15 Oct+20trend state cleared (trend down 10d no longer applied)
- 14 Oct-15Stock Condition eased 15 points on shifts across underlying measured values
- 13 Oct+8Stock Condition rose 8 points on shifts across underlying measured values
- 12 Oct+6rsi state cleared (rsi oversold zone no longer applied)
- 09 Oct-9Stock Condition eased 9 points on shifts across underlying measured values
- 08 Oct+1RSI entered its lower zone
- 07 Oct-5options positioning turned call-heavy
- 06 Oct+6options state cleared (pcr call heavy no longer applied)
Related news
- highregulatorythehindubusinessline.com· 02 Nov 2026, 08:52 pmCipla tops drug overcharging dues with ₹3,576 crore; J&J, Ranbaxy among top five
- loweconomictimes.indiatimes.com· 28 Oct 2026, 05:49 amCipla’s US recovery, biosimilar pipeline key to future growth prospects
- highcorporate actioneconomictimes.indiatimes.com· 27 Oct 2026, 01:41 pmCipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
- loweconomictimes.indiatimes.com· 26 Oct 2026, 05:31 amNifty outlook bearish, but near-term recovery in sight: Analysts
- loweconomictimes.indiatimes.com· 19 Oct 2026, 05:59 amPharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
- lowlivemint.com· 14 Oct 2026, 01:15 pmMutual funds' September 2026 portfolio moves: Top 5 stocks bought and sold across large-, mid- and small-cap segments